<h4>Background</h4>Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death with type 2 diabetes; however, their effect on arrhythmias is unclear. Here, SLC5A2 is linked to type 2 diabetes mellitus.